Press Releases
Back to Press Releases >
BioRestorative Therapies Appoints Wayne Olan, M.D. to Scientific Advisory Board
BioRestorative Therapies
BioRestorative Therapies Appoints Wayne Olan, M.D. to Scientific Advisory Board

JUPITER, Fla. (April 14, 2014) - BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTCBB: BRTX), a life sciences company focused on adult stem cell-based therapies for various personal medical applications, today announced that Wayne Olan, M.D has been appointed as a member of the Company's Scientific Advisory Board ("SAB").

Dr. Olan, a board-certified Interventional Neuroradiologist, is the director of endovascular and minimally invasive image guided neurosurgery in Washington, D.C. at the George Washington University Medical Center, and is also an associate professor at The George Washington University School of Medicine & Health Sciences. Dr. Olan also serves as a consulting physician to the National Institutes of Health.

Dr. Olan was the director of interventional neuroradiology at Suburban Hospital in Bethesda, Maryland from 1999 to 2010. He is a member of many professional societies including the Radiological Society of North America, American College of Radiology, American Medical Association, Medical Society of District of Columbia, American Society of Neuroradiology, and American Society of Spine Radiology.

Dr. Olan has over 150 published papers, posters, abstracts and lectures on endovascular treatment of cerebrovascular disorders, including the treatment of cerebral aneurysms, arteriovenous malformations, and the treatment of stroke. A great deal of his research has covered the interventional treatment of spinal disorders.

Dr. Wayne Marasco, Chairman of BRT's Scientific Advisory Board said, "Dr. Olan's expertise in minimally invasive neurosurgery and spine disease is a strong addition to the BRT team on several fronts. His experience in interventional treatments for the spine is a welcome addition to our SAB, and will prove invaluable as we prepare to file for approval from the U.S. Food and Drug Administration to begin our brtxDISC™ clinical trials for the treatment of protruding, bulging and herniated lumbar discs."

Dr. Olan received his M.D. degree from University of Health Science, the Chicago Medical School. He completed his training in radiology and fellowship training in neuroradiology with subspecialty training in interventional neuroradiology.

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. ( develops products and medical procedures using cell and tissue protocols, primarily involving adult stem cells, including:

brtxDISC™ (DiscImplantedStemCells) is an investigational non-surgical treatment for protruding, bulging and herniated lumbar discs that is intended for patients who have failed non-invasive procedures and face the prospect of surgery. The treatment involves culturing a patient's own stem cells and then delivering them via a proprietary medical device to the damaged region of the disc in an outpatient procedure.
ThermoStem® is a treatment using brown fat stem cells that is under development for metabolic disorders including diabetes and obesity. Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels.
brtx-C Cosmetic is based on the development of a human cellular extract that has been demonstrated in in vitro skin studies to increase the production of collagen and fibronectin, which are proteins that are essential to combating the aging of skin. Potential cosmetic uses are being explored with third parties.

The Company also offers plant stem cell-based facial creams and beauty products under the Stem Pearls® brand at

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

Investor Contacts:

Kim Sutton Golodetz
Bruce Voss

# # #

BioRestorative Therapies: A Stem Cell Biotechnology Company